Marlborough Pharmaceutical Company Sells Its Asthma Drug Rights

Image via Shutterstock

Akorn Inc. is expected to pay $45 million to Marlborough-based pharmaceutical company Sunovion for the rights to its drug Xopenex Inhalation Solution, reported the Worcester Business Journal.

The drug is used to treat airway diseases such as asthma in adults and children six and older. Akorn is based in Illinois and said it plans to ship the drug out to patients as soon as the deal is closed.

Sunovion has nine products approved by the Federal Food and Drug Administration, including Aption and Lunesta.